At week 6 , 1 % terbinafine FFS was clinically superior to placebo for the absence of : erythema ( 69 vs. 29 % ) ; desquamation ( 33 vs. 8 % ) ; and pruritus ( 70 vs. 30 % ) : all p 0.001 and clinically relevant .